(CRDF) – Company Press Releases
-
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
-
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
-
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
-
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
-
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
-
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference
-
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update
-
Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research
-
Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference
-
Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update
-
Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update
-
Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy
-
Cardiff Oncology to Present at Upcoming Investor Conferences in September
-
Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update
-
Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship
-
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Cardiff Oncology to Present at the Jefferies Healthcare Conference
-
Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update
-
Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal Cancer
-
Cardiff Oncology Formally Introduces Scientific Advisory Board
-
Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
-
Cardiff Oncology to Present at the Cowen 43rd Annual Health Care Conference
-
Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer
-
Cardiff Oncology to Present at B. Riley Securities' 3rd Annual Oncology Conference
-
Cardiff Oncology to Present at Upcoming Investor Conferences
-
Cardiff Oncology to Present at the Jefferies London Healthcare Conference
-
Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates
-
Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates
-
Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022
-
Cardiff Oncology to Present at Upcoming Investor Conferences in September
-
Cardiff Oncology Announces Upcoming Poster Presentations at the ESMO Congress 2022
-
Cardiff Oncology to Host Webcast and Conference Call to Provide a Clinical and Corporate Update on September 12, 2022
-
Cardiff Oncology Reports Second Quarter 2022 Results and Provides Business Updates
-
Cardiff Oncology to Present at the William Blair Biotech Focus Conference 2022
-
Cardiff Oncology to Present at the H.C. Wainwright Global Investment Conference
-
Cardiff Oncology Reports First Quarter 2022 Results and Provides Business Updates
-
Cardiff Oncology Announces Departure of Chief Medical Officer
-
Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting
-
Cardiff Oncology Announces Data Showing the Combination of PARP Inhibition with Onvansertib Overcomes PARP Inhibitor Resistance in BRCA1-mutant and Wildtype Patient-Derived Xenograft Ovarian Cancer Mo
-
Cardiff Oncology to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC
-
Cardiff Oncology Announces Upcoming Poster Presentations at the AACR Annual Meeting
-
Cardiff Oncology to Participate in Cowen's 42nd Annual Healthcare Conference
-
Cardiff Oncology Reports Fourth Quarter and Full Year 2021 Results and Recent Highlights
-
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Cardiff Oncology to Present at the B. Riley Securities 2022 Oncology Conference
-
Cardiff Oncology Announces New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival
-
Cardiff Oncology Appoints Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, RPh, as Senior Vice President, Regulatory Affairs
-
Cardiff Oncology to Host Conference Call and Webcast to Discuss Updated Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Being Presented at the 2022 American Society of Cli
-
Cardiff Oncology to Present at the H.C. Wainwright BioConnect Virtual Conference
Back to CRDF Stock Lookup
